CB2 Receptor

The CB2 receptor was discovered in 1993, five years after CB1, when researchers identified a second cannabinoid receptor distributed primarily in immune system tissues rather than the brain. CB2 represents the therapeutic Holy Grail of cannabinoid medicine — activating it produces meaningful clinical benefits (anti-inflammatory, neuroprotective, immune modulation) without psychoactive side effects. Distribution: CB2 receptors are concentrated in spleen, thymus, lymph nodes, tonsils, immune cells (B-cells, T-cells, macrophages, microglia), gastrointestinal tract, peripheral nervous system, bone (osteoblasts, osteoclasts), liver, pancreas, and cardiovascular tissue. Brain CB2 expression is much lower than CB1 but increases dramatically during inflammation, neurodegeneration, and brain injury — creating an "induced" CB2 system that activates only when needed for therapeutic intervention. Mechanism: CB2 activation reduces inflammatory cytokine release (TNF-alpha, IL-6, IL-1beta), shifts immune system polarization from pro-inflammatory to anti-inflammatory, modulates pain at peripheral nerve endings without central nervous system depression, promotes bone formation and reduces bone resorption, supports gut barrier function and reduces inflammatory bowel disease symptoms, and provides neuroprotection in stroke, Alzheimer's, and Parkinson's disease models. Therapeutic applications: chronic inflammatory diseases (arthritis, IBD, multiple sclerosis), neurodegenerative diseases (Alzheimer's, ALS, Parkinson's), neuropathic pain syndromes, autoimmune conditions, osteoporosis, fibromyalgia, and addiction treatment (CB2 agonists reduce cocaine and alcohol-seeking behavior). Cannabis compounds that target CB2: CBD has weak CB2 affinity but enhances endogenous CB2 signaling; CBG has moderate CB2 binding; CBC binds CB2 with reasonable affinity; beta-caryophyllene is a full CB2 agonist (the first dietary cannabinoid identified). Pharmaceutical CB2 agonists are in development for chronic pain, autoimmune disease, and neuroinflammation, but full-spectrum cannabis with high CB2-targeting compounds remains the most accessible CB2 therapy currently available.